Tulane University

A phase 1 study, conducted in the United States, of adults that had not been exposed to hookworm was performed from 2005-2006. 
Sample: 
- 36 healthy adults

Methods:
- randomized, double-blind, placebo-controlled study 
- 3 different concentrations of Na-ASP-2 were used
- patients were observed after 6 months of administering the vaccine

Safety Profile:
The vaccine was efficacious and safe. Adverse events included injection site reactions, swelling, erythema and pruritus. 


Phase 1 Study

Stanley Plotkin, David J. Diemert, Jeffrey M. Bethony, Peter J. Hotez, Hookworm Vaccines, Clinical Infectious Diseases, Volume 46, Issue 2, 15 January 2008, Pages 282–288, https://doi.org/10.1086/524070

Hookworm Vaccines

Vaccination induced significant IgG antibody and cell mediated immune responses. Vaccine efficacy is determined upon quantitative analysis of fecal egg counts (measures worm burden and indirectly measures disease burden). Analysis of these egg counts will occur at a specific time following vaccination that will be chosen based on epidemiologically determined rates of reinfection.  The Na-ASP-2 vaccine will only affect the larval stage of hookworm infections and is not isolated to adult hookworms that are already present in the host’s GI tract. Therefore, deworming is a necessary public health measure that needs to take place in order to eliminate adult worms before the patient is vaccinated. 

Learn Before

Related